Legend Biotech 

Yahoo Finance • 24 days ago

Sector Update: Health Care Stocks Rise Friday Afternoon

Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 30 days ago

The Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma Expertise

On August 18, 2025, Legend Biotech appointed Carlos Santos as Chief Financial Officer and principal accounting officer, succeeding interim CFO Jessie Yeung, bringing decades of finance leadership from AstraZeneca, Novartis, and Intel to th... Full story

Yahoo Finance • last month

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Legend Biotech USA Inc. SOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive O... Full story

Yahoo Finance • last month

Legend Biotech appoints Carlos Santos as CFO

[concept word CFO on cubes.close up of wooden elements,Business Concept.3D rendering on blue background.] Legend Biotech (NASDAQ:LEGN [https://seekingalpha.com/symbol/LEGN]) has appointed [https://seekingalpha.com/pr/20203488-legend-biote... Full story

Yahoo Finance • last month

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company’s Chief Financial Officer, eff... Full story

Yahoo Finance • 2 months ago

Germany stocks higher at close of trade; DAX up 0.75%

Investing.com – Germany stocks were higher after the close on Thursday, as gains in the Financial Services, Food & Beverages and Industrials sectors led shares higher. At the close in Frankfurt, the DAX added 0.75% to hit a new 1-month hi... Full story

Yahoo Finance • 2 months ago

Legend Biotech Corp (LEGN) Q2 2025 Earnings Call Highlights: Record CARVYKTI Sales and ...

CARVYKTI Net Trade Sales: $439 million, a 136% increase year over year. Total Revenues: $255 million, driven by collaboration revenue growth of 136% year over year. Net Loss: $125 million, with an adjusted net income of $10 million after e... Full story

Yahoo Finance • 2 months ago

Legend Bio earnings missed by $0.22, revenue topped estimates

Investing.com - Legend Bio (NASDAQ: LEGN) reported second quarter EPS of $-0.34, $0.22 worse than the analyst estimate of $-0.12. Revenue for the quarter came in at $255.06M versus the consensus estimate of $234.23M. Legend Bio’s stock pr... Full story

Yahoo Finance • 2 months ago

Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q2 2025 Earnings with Revenue Beat and EPS Miss Amid Strong CARVYKTI Sales

LEGEND BIOTECH CORP. (NASDAQ:LEGN [https://www.chartmill.com/stock/quote/LEGN]) REPORTS Q2 2025 EARNINGS: REVENUE BEATS, EPS MISSES AMID STRONG CARVYKTI SALES Legend Biotech Corp. released its second-quarter 2025 financial results, delive... Full story

Yahoo Finance • 2 months ago

Legend Biotech GAAP EPS of -$0.34 misses by $0.14, revenue of $255.06M beats by $26.6M

* Legend Biotech press release [https://seekingalpha.com/pr/20195737-legend-biotech-reports-second-quarter-2025-results-and-recent-highlights] (NASDAQ:LEGN [https://seekingalpha.com/symbol/LEGN]): Q2 GAAP EPS of -$0.34 misses by $0.14.... Full story

Yahoo Finance • 2 months ago

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 yearsPresent... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Lithium Argentina AG (LAC [https://seekingalpha.com/symbol/LAC]) * Ballard Power Systems (BLDP [https://seekingalpha.com/symbol/BLDP]) * Franco-Nevada Corporation (FNV [ht... Full story

Yahoo Finance • 2 months ago

Legend Biotech's SWOT analysis: stock poised for growth amid challenges

Legend Biotech Corporation (NASDAQ:LEGN), a $7.75 billion biotechnology company focused on developing novel cell therapies for oncology and other indications, has been making significant strides in the treatment of multiple myeloma with it... Full story

Yahoo Finance • 2 months ago

Goldman Sachs reiterates buy rating on Legend Biotech stock after strong Carvykti sales

Investing.com - Goldman Sachs has reiterated its Buy rating and $74.51 price target on Legend Biotech Corp . (NASDAQ:LEGN), a $7.3 billion market cap biotech company, following strong preliminary second-quarter sales of its cancer therapy... Full story

Yahoo Finance • 3 months ago

These companies are most likely to surprise in real estate H1 earnings season

Investing.com -- Bernstein expects a mixed but potentially positive first-half earnings season for the European real estate sector, highlighting nine companies that could raise their guidance. The firms that are “most likely to surprise”... Full story

Yahoo Finance • 3 months ago

Legend Biotech stock price target lowered to $54 at UBS on growth concerns

Investing.com - UBS has lowered its price target on Legend Biotech Corp . (NASDAQ:LEGN) to $54.00 from $60.00 while maintaining a Buy rating on the stock. According to InvestingPro data, the company has demonstrated strong revenue growth... Full story

Yahoo Finance • 3 months ago

Germany stocks lower at close of trade; DAX down 1.12%

Investing.com – Germany stocks were lower after the close on Thursday, as losses in the Construction, Retail and Software sectors led shares lower. At the close in Frankfurt, the DAX lost 1.12% to hit a new 1-month low, while the MDAX ind... Full story

Yahoo Finance • 4 months ago

Legend Biotech's SWOT analysis: carvykti's strong performance drives stock potential

Legend Biotech Corporation (NASDAQ:LEGN), a prominent player in the U.S. Small & Mid Cap Biotechnology sector, has been making significant strides in the development and commercialization of novel cell therapies for oncology and other indi... Full story

Yahoo Finance • 4 months ago

Thursday's ETF with Unusual Volume: FTQI

The First Trust Nasdaq BuyWrite Income ETF is seeing unusually high volume in afternoon trading Thursday, with over 909,000 shares traded versus three month average volume of about 226,000. Shares of FTQI were down about 0.2% on the day.... Full story

Yahoo Finance • 4 months ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years CARTITUDE-4 subgroup analyses... Full story